Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS)

Tomohisa Egawa, Takeshi Kenmochi, Masaki Ohashi, Tomoyuki Irino, Koki Mihara, Akihiko Okamura, Yusaku Inaba, Yasuhiro Ito, Shinobu Hayashi, Atsushi Nagashima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 60-year-old male was found to have advanced gastric cancer and multiple lymph node metastases. Since curative surgery was concluded to be unfeasible, we tried neoadjuvant chemotherapy with the aim of controlling the lymph node metastasis. S-1 (80 mg/m2) was administered orally for two weeks then followed by 2-week rest period. CDDP (60 mg/ m2) and docetaxel (40 mg/m2) were simultaneously administered on day 1. Two courses of treatment resulted in marked shrinkage of the primary lesion and a reduction in size of the lymph nodes. The results were evaluated as a clinical PR based on RECIST, and radical resection was considered possible. The patient experienced a grade 3 leukocytopenia and neutropenia as adverse events of the chemotherapy. Total gastrectomy, splenectomy, and D2 lymph node dissection were performed with curative intent, and the postoperative course was uneventful. Histological examination of the surgical specimens revealed almost complete disappearance of cancer cells in the primary lesion in the stomach and complete disappearance in the lymph nodes. Pathological efficacy was Grade 2. The patient experienced a grade 3 appetite loss, and the adjuvant chemotherapy (S-1 regimen) was discontinued. The patient died of peritoneal dissemination eight months after the operation. We concluded that DCS as neoadjuvant chemotherapy was a promising strategy for patients with highly advanced gastric cancer because of its rapid antitumor effect.

Original languageEnglish
Pages (from-to)2470-2472
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume37
Issue number12
Publication statusPublished - 2010 Jan 1
Externally publishedYes

Fingerprint

docetaxel
Combination Drug Therapy
Stomach Neoplasms
Lymph Nodes
Drug Therapy
Neoplasm Metastasis
Leukopenia
Appetite
Splenectomy
Gastrectomy
Adjuvant Chemotherapy
Neutropenia
Lymph Node Excision
Stomach

Keywords

  • Gastric cancer
  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Egawa, T., Kenmochi, T., Ohashi, M., Irino, T., Mihara, K., Okamura, A., ... Nagashima, A. (2010). Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS). Japanese Journal of Cancer and Chemotherapy, 37(12), 2470-2472.

Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS). / Egawa, Tomohisa; Kenmochi, Takeshi; Ohashi, Masaki; Irino, Tomoyuki; Mihara, Koki; Okamura, Akihiko; Inaba, Yusaku; Ito, Yasuhiro; Hayashi, Shinobu; Nagashima, Atsushi.

In: Japanese Journal of Cancer and Chemotherapy, Vol. 37, No. 12, 01.01.2010, p. 2470-2472.

Research output: Contribution to journalArticle

Egawa, T, Kenmochi, T, Ohashi, M, Irino, T, Mihara, K, Okamura, A, Inaba, Y, Ito, Y, Hayashi, S & Nagashima, A 2010, 'Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS)', Japanese Journal of Cancer and Chemotherapy, vol. 37, no. 12, pp. 2470-2472.
Egawa, Tomohisa ; Kenmochi, Takeshi ; Ohashi, Masaki ; Irino, Tomoyuki ; Mihara, Koki ; Okamura, Akihiko ; Inaba, Yusaku ; Ito, Yasuhiro ; Hayashi, Shinobu ; Nagashima, Atsushi. / Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS). In: Japanese Journal of Cancer and Chemotherapy. 2010 ; Vol. 37, No. 12. pp. 2470-2472.
@article{80bdf01e6726476686bd02b63ec78e32,
title = "Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS)",
abstract = "A 60-year-old male was found to have advanced gastric cancer and multiple lymph node metastases. Since curative surgery was concluded to be unfeasible, we tried neoadjuvant chemotherapy with the aim of controlling the lymph node metastasis. S-1 (80 mg/m2) was administered orally for two weeks then followed by 2-week rest period. CDDP (60 mg/ m2) and docetaxel (40 mg/m2) were simultaneously administered on day 1. Two courses of treatment resulted in marked shrinkage of the primary lesion and a reduction in size of the lymph nodes. The results were evaluated as a clinical PR based on RECIST, and radical resection was considered possible. The patient experienced a grade 3 leukocytopenia and neutropenia as adverse events of the chemotherapy. Total gastrectomy, splenectomy, and D2 lymph node dissection were performed with curative intent, and the postoperative course was uneventful. Histological examination of the surgical specimens revealed almost complete disappearance of cancer cells in the primary lesion in the stomach and complete disappearance in the lymph nodes. Pathological efficacy was Grade 2. The patient experienced a grade 3 appetite loss, and the adjuvant chemotherapy (S-1 regimen) was discontinued. The patient died of peritoneal dissemination eight months after the operation. We concluded that DCS as neoadjuvant chemotherapy was a promising strategy for patients with highly advanced gastric cancer because of its rapid antitumor effect.",
keywords = "Gastric cancer, Neoadjuvant chemotherapy",
author = "Tomohisa Egawa and Takeshi Kenmochi and Masaki Ohashi and Tomoyuki Irino and Koki Mihara and Akihiko Okamura and Yusaku Inaba and Yasuhiro Ito and Shinobu Hayashi and Atsushi Nagashima",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "37",
pages = "2470--2472",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "12",

}

TY - JOUR

T1 - Highly advanced gastric cancer that responded to neoadjuvant combination chemotherapy with docetaxel/CDDP/S-1 (DCS)

AU - Egawa, Tomohisa

AU - Kenmochi, Takeshi

AU - Ohashi, Masaki

AU - Irino, Tomoyuki

AU - Mihara, Koki

AU - Okamura, Akihiko

AU - Inaba, Yusaku

AU - Ito, Yasuhiro

AU - Hayashi, Shinobu

AU - Nagashima, Atsushi

PY - 2010/1/1

Y1 - 2010/1/1

N2 - A 60-year-old male was found to have advanced gastric cancer and multiple lymph node metastases. Since curative surgery was concluded to be unfeasible, we tried neoadjuvant chemotherapy with the aim of controlling the lymph node metastasis. S-1 (80 mg/m2) was administered orally for two weeks then followed by 2-week rest period. CDDP (60 mg/ m2) and docetaxel (40 mg/m2) were simultaneously administered on day 1. Two courses of treatment resulted in marked shrinkage of the primary lesion and a reduction in size of the lymph nodes. The results were evaluated as a clinical PR based on RECIST, and radical resection was considered possible. The patient experienced a grade 3 leukocytopenia and neutropenia as adverse events of the chemotherapy. Total gastrectomy, splenectomy, and D2 lymph node dissection were performed with curative intent, and the postoperative course was uneventful. Histological examination of the surgical specimens revealed almost complete disappearance of cancer cells in the primary lesion in the stomach and complete disappearance in the lymph nodes. Pathological efficacy was Grade 2. The patient experienced a grade 3 appetite loss, and the adjuvant chemotherapy (S-1 regimen) was discontinued. The patient died of peritoneal dissemination eight months after the operation. We concluded that DCS as neoadjuvant chemotherapy was a promising strategy for patients with highly advanced gastric cancer because of its rapid antitumor effect.

AB - A 60-year-old male was found to have advanced gastric cancer and multiple lymph node metastases. Since curative surgery was concluded to be unfeasible, we tried neoadjuvant chemotherapy with the aim of controlling the lymph node metastasis. S-1 (80 mg/m2) was administered orally for two weeks then followed by 2-week rest period. CDDP (60 mg/ m2) and docetaxel (40 mg/m2) were simultaneously administered on day 1. Two courses of treatment resulted in marked shrinkage of the primary lesion and a reduction in size of the lymph nodes. The results were evaluated as a clinical PR based on RECIST, and radical resection was considered possible. The patient experienced a grade 3 leukocytopenia and neutropenia as adverse events of the chemotherapy. Total gastrectomy, splenectomy, and D2 lymph node dissection were performed with curative intent, and the postoperative course was uneventful. Histological examination of the surgical specimens revealed almost complete disappearance of cancer cells in the primary lesion in the stomach and complete disappearance in the lymph nodes. Pathological efficacy was Grade 2. The patient experienced a grade 3 appetite loss, and the adjuvant chemotherapy (S-1 regimen) was discontinued. The patient died of peritoneal dissemination eight months after the operation. We concluded that DCS as neoadjuvant chemotherapy was a promising strategy for patients with highly advanced gastric cancer because of its rapid antitumor effect.

KW - Gastric cancer

KW - Neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84866615187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866615187&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 2470

EP - 2472

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -